About this trial
This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.
Eligibility criteria
Qualifiers
Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC<70%, FEV1% predicted value ≤ 50% after Bronchiectasis)
Age>40 years old
COPD stable for more than 4 weeks
Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month
Disqualifiers
Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis
Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease)
History of chronic diarrhea or constipation
History of Gastrointestinal Surgery
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Li An
Lead sponsor
Beijing Chao Yang Hospital
Sponsor institution